logo
logo

Chrysalis BioTherapeutics Receives Additional Funding from the National Institutes of Health for COVID-19 Therapeutic Development

Chrysalis BioTherapeutics Receives Additional Funding from the National Institutes of Health for COVID-19 Therapeutic Development

08/11/20, 3:06 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svggalveston
Money raised
$0
Industry
biotechnology
healthcare
Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company developing regenerative drugs that target vascular endothelial and progenitor cells, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has provided additional funding in the amount of $587,995 to its contract with Chrysalis, bringing the total contract award to develop TP508 as a therapeutic for COVID-19 patients to $1.5 million.

Company Info

Company
Chrysalis Bio Therapeutics
Location
2200 market st, suite 606
galveston, texas, united states
Additional Info
Chrysalis BioTherapeutics, Inc. is a biopharmaceutical development company located in Galveston, TX. TP508 (rusalatide acetate) is licensed from The University of Texas Medical Branch (UTMB) at Galveston, TX. Although TP508 has shown potential efficacy in stimulating early tissue repair in human clinical trials, it is not yet FDA-approved and is currently only available for investigational use.

Related People